Ongoing Clinical Trials
Multiple Sclerosis (MS) - Ongoing Trials
-Enrollment Open
Volunteers for trials are welcome.
Please contact Mildred Valentine
(773-702-9812).
FTY720 in Relapsing/Remitting MS (Oral Treatment)
New experimental drug taken orally for relapsing/remitting MS.
This two year research study will determine if a new experimental drug taken by
mouth once daily can reduce the number of relapses in patients with relapsing/remitting MS.
It will also evaluate how safe and well tolerated the experimental drug is when used for
up to two years.
Selection Criteria:
- 18 to 55 years old
- Relapsing/Remitting MS
- EDSS score: 0 to 5.5 (able to walk 100 meters without aids)
- Must be available for clinic visits for the duration of the study
Principal investigator: Anthony Reder, M.D.
Study coordinator: Mildred Valentine - 773-702-9812
Single vs. Double-dose Copaxone for Relapsing/Remitting MS
This two year study will determine if an experimental dose
of Copaxone is safe, tolerable,
and more effective than the currently approved dose.
Selection Criteria:
- 18 to 55 years old
- Relapsing/Remitting MS
- EDSS (expanded disability status score) 0 to 5.0
(able to walk 200 meters without assistance)
- Never on any therapy for MS (other than steriods more than 3 months ago)
Principal Investigator: Adil Javed, MD
Project coordinator: Krystal Ivy (773) 834-4652
Ongoing Trials for Multiple Sclerosis (MS) - Enrollment Closed
Anti-B Cell Antibody (Rituxan) for Progressive MS
The purpose of this study is to investigate an Anti-B cell
antibody in the treatment of Primary Progressive MS.
Selection Criteria:
- 2 1/2 year study
- 18 to 65 years old
- Not on any therapy for MS three months before screening
- Primary Progressive MS
- EDSS (Expanded Disability Status Scale) 2.0 to 6.5
- Constant bilateral support (cane, crutches, braces) required
to walk 20m without resting, or better.
Principal investigator: Anthony Reder, M.D.
Sub-investigators: Barry G.W. Arnason, M.D. Avertano Noronha, MD
and Adil Javed, MD
Study coordinator: Mildred Valentine - 773-702-9812
BEYOND Study for Relapsing/Remitting MS
Enrollment closed. Study on-going.
The purpose of this two year study is to determine:
1. If an experimental dose of a currently approved drug is safe,
tolerable, and more effective than the currently approved dose.
2. Which of two commonly used drugs is safer, more tolerable,
and more effective in treating this disease.
Selection criteria:
- 18 to 55 years old
- No treatment for MS within past 3 months
- Relapsing/remitting MS (symptoms flare up and then become more stable)
- EDSS (expanded disability status scale) 0 to 5.0
(able to walk 200 meters without assistance
Principal investigator: Barry G.W. Arnason, M.D.
Sub-investigators: Anthony Reder, M.D.
Avertano Noronha, MD
Roumen Balabanov, MD;
Agnes Kim, MD; Darshan Shah, MD;
Adil Javed, MD.
Study coordinator: Mildred Valentine (773) 702-9812
Novantrone in MS
Enrollment closed. Study on-going.
This is a phase IV monitoring study of the effects of
Mitoxantrone/Novantrone in active MS.
This drug was recently
approved by the FDA, and is a form of chemotherapy that
reduces the white blood cells that attack the brain. WBC, liver function, and cardiac
function will be monitored.
Selection criteria include:
- Age 18-65.
-Exclusion: primary progressive MS, heart disease.
Principal investigator: Anthony Reder, M.D.
Rebif vs Copaxone in Relapsing/Remitting MS
Enrollment closed. Data being analyzed.
The purpose of this study is to compare the safety and
effectiveness of two
FDA approved drugs for the treatment
of relapsing/remitting MS.
Selection criteria:
- 18 to 60 years old
- Not on any therapy for MS
- Repapsing/remitting MS (symptoms flare up and then get somewhat better)
-EDSS (expanded disability status scale) 0 to 5.0 (able to walk 200 meters without assistance)
Principal investigator: Anthony Reder, M.D.
Sub-investigators: Barry G.W. Arnason, M.D.
and Avertano Noronha, MD
Study coordinator: Mildred Valentine
- 773-702-9812
|
|
|
|
|
 |
Send This To A Friend |
|
|
